retatrutide clinical trials safety retatrutide How to Get in 2026 This weight-loss drug hasn't been

Marquez-Meneses JD, Olaya-Bonilla SA, Barrera-Carreo S, Tibaduiza-Arvalo LC, Forero-Crdenas S, Carrillo-Vaca L, Rojas-Rodrguez LC, Calderon-Ospina CA, Rodrguez-Quintana J (2025) GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial [published correction appears in lancet

Company Details does not have an official, publicly published logo associated with its corporate entity

Not all patients require the maximum dose